poltmachine.blogg.se - Recommended citation for nccn guidelines using zotero

RECOMMENDED CITATION FOR NCCN GUIDELINES USING ZOTERO UPDATE
RECOMMENDED CITATION FOR NCCN GUIDELINES USING ZOTERO SERIES

Sun L, Brentnall A, Patel S, Buist DS, Bowles EJ, Evans DG, et al.Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A, et al.A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Buys SS, Sandbach JF, Gammon A, Patel G, Kidd J, Brown KL, et al.American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility.

Robson ME, Bradbury AR, Arun B, Domchek SM, Ford JM, Hampel HL, et al.Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. Kurian AW, Hare EE, Mills MA, Kingham KE, McPherson L, Whittemore AS, et al.Inherited Mutations in Women With Ovarian Carcinoma. Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, et al.Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al.A systematic review of the international prevalence of BRCA mutation in breast cancer. Armstrong N, Ryder S, Forbes C, Ross J, Quek RG.

RECOMMENDED CITATION FOR NCCN GUIDELINES USING ZOTERO SERIES

Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.

Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al.

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al.

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.

Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, et al.

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.

Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al.

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.

Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al.

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al.

Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations.

Schrag D, Kuntz KM, Garber JE, Weeks JC.

Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement. Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, et al.Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. Tung NM, Boughey JC, Pierce LJ, Robson ME, Bedrosian I, Dietz JR, et al.Available from: Ordinanza del DFI sulle prestazioni dell’assicurazione obbligatoria delle cure medico-sanitarie. Available from: Ordonnance du DFI sur les prestations dans l’assurance obligatoire des soins en cas de maladie. Verordnung des EDI über Leistungen in der obligatorischen Krankenpflegeversicherung.

RECOMMENDED CITATION FOR NCCN GUIDELINES USING ZOTERO UPDATE

Clinical guideline (CG164), last update 20 November 2019. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer.

National Institute for Health and Clinical Excellence (NICE).

Genetic/familial high-risk assessment: Breast, Ovarian, and Pancreatic Version 2.2021.

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology.

It aims to help providers of genetic counselling to identify valuable candidates for testing and serves as a basis for reimbursement claims to Swiss insurance companies. This paper presents the Swiss guideline for genetic counselling and testing of individuals with an increased probability for carrying mutations in high risk cancer predisposition genes, particularly BRCA1 and BRCA2.